Lynparza receives positive EU CHMP opinion for 1st
29 April 2019 07:00 BST Lynparza receives positive EU CHMP opinion for 1st-linemaintenance treatment of BRCA-mutated advanced ovarian cancer AstraZeneca and MSD's Lynparza is the only PARP inhibitor to demonstratean improvement in progression-free survival for patients in this setting AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending Lynparza(olaparib) as a 1st-line